Response to Letter to the Editor: “Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline”-Reference-Cited by-同舟云学术

Response to Letter to the Editor: “Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline”

Published:2019-04-18 Issue:8 Volume:104 Page:3537-3538
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Eastell Richard¹,Rosen Clifford J²^ORCID

Affiliation:

1. Academic Unit of Bone Metabolism, Mellanby Centre for Bone Research and Metabolic Bone Centre, Northern General Hospital, Sheffield, United Kingdom

2. Department of Medicine, Tufts University School of Medicine, Maine Medical Center Research Institute, Scarborough, Maine

Publisher

The Endocrine Society

Subject

Biochemistry, medical,Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/jc.2019-00777/28475070/jc.2019-00777.pdf

Reference10 articles.

1. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis;Barrionuevo;J Clin Endocrinol Metab,2019

2. Women’s values and preferences regarding osteoporosis treatments: a systematic review;Barrionuevo;J Clin Endocrinol Metab,2019

3. Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women;Freemantle;Osteoporos Int,2012

4. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study;Hadji;Osteoporos Int,2015